MyFinsight
Home
Blog
About
Issuance of series a
convertible preferred stock
$9,000,000
Net cash flows
provided by financing...
$8,425,786
Canceled cashflow
$574,214
Net increase in cash
and cash...
$6,310,112
(653.37%↑ Y/Y)
Canceled cashflow
$2,115,674
Repayment of notes payable
related party
$499,214
Deferred financing costs
$75,000
Accrued expenses
$272,474
(384.37%↑ Y/Y)
Stock-based compensation
expense
$144,094
Accounts payable
$127,589
(258.72%↑ Y/Y)
Inventory write-off
$42,372
Inventories
-$39,152
Change in fair value of
derivative liabilities and...
-$275
(99.90%↑ Y/Y)
Net cash flows used
in operating...
-$2,115,674
(-85.53%↓ Y/Y)
Canceled cashflow
$625,956
Net loss
-$1,268,142
(35.99%↑ Y/Y)
(gain) loss on
extinguishment of debt
$1,115,455
(406.35%↑ Y/Y)
something is missing
-$238,224
Prepaid expenses and
other current assets
$119,809
Back
Back
Cash Flow
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)
source: myfinsight.com